TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of CLA Supplements on Body Weight and Fat Oxidation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 25-29.9 kg/m2~* Absence of a weight change of greater than 3 kg in the previous 6 months~Exclusion Criteria:~* Presence of a physical limitation to walking exercise~* Current or recent (6 months) enrollment in a commercial or self-prescribed weight loss program~* A history of metabolic disease-ie. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study~* A history of a psychiatric or eating disorders Ÿ Presence of metal implants that would interfere with body composition analysis~* Fasting plasma cholesterol \>300mg/dl or triglycerides above 500 mg/dl.~* Abnormal EKG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- CLA treatment (Type: ACTIVE_COMPARATOR): The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): The group randomized to control received 4 g/d of safflower oil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent is obtained before conducting any study-related procedures~* The patient is a man or woman aged 18 to 80 years as of the screening visit~* The patient is experiencing non-specific respiratory symptoms defined as follows: Cough and/or wheeze and/or chronic dyspnoea for ≥ 6 weeks prior to visit 1~* Patients displaying an FEV1\< 90% predicted at visit 1, will also need to show a reversibility to a short-acting beta-agonist of \< 20% at visit 1 or within the previous year~* Women of childbearing potential (post-menarche or less than 2 years post-menopausal or not surgically sterile) must be willing to commit to using a medically accepted method of contraception for the duration of the study. Accepted methods of contraception include: intrauterine devices (IUD), systemic contraception e.g. steroidal contraceptives (oral, implanted transdermal or injected), barrier methods with spermicide, and partner vasectomy~Exclusion Criteria:~* The patient has ever been diagnosed with asthma as evidenced by the UK quality outcome framework approved Read code as well as a reversibility of ≥ 20% predicted~* The patient has received oral, inhaled or systemic corticosteroids, a leukotriene modifier or long-acting-beta-agonist within four weeks prior to visit 1. All therapy and treatment other than those outlined are permitted during the study~* The patient has a significant chronic respiratory disorder other than asthma, e.g. COPD (fixed obstruction, post-bronchodilator) cystic fibrosis, severe and untreated bronchiectasis or interstitial lung disease~* The patient has a significant medical condition that would make it unlikely for the patient to complete the study~* The patient has a known significant risk factor for cough or wheeze, including but not limited to: taking an ACE inhibitor, severe untreated rhinitis, or significant gastroesophageal reflux disease~* The patient is asymptomatic (ACQ \< 1) after the initial 2-week assessment~* The patient has had a respiratory tract infection as judged clinically, within four weeks prior to visit 1, or displays an acute respiratory tract infection at the time of the study~* The patient is a pregnant woman or intends to get pregnant (Any woman becoming pregnant during the study will be withdrawn from the study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): 4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
- Placebo (Type: NO_INTERVENTION): Blinded placebo inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor for PCI Post Thrombolysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and over.~2. Planned PCI between 4-24 hours after administration of fibrinolytic therapy for STEMI.~3. Treatment with aspirin and clopidogrel as an adjunct to fibrinolytic therapy.~4. Informed written consent.~Exclusion Criteria:~1. Atrial fibrillation or need for systemic anticoagulation therapy.~2. Prior PCI or coronary artery bypass grafting during past 3 months.~3. Active bleeding or high risk of bleeding based upon clinical assessment.~4. Known severe liver or renal disease or patient requiring dialysis.~5. Concomitant oral or IV therapy with strong cytochrome (CYP3A) inhibitors which cannot be stopped.~6. Contraindication to ticagrelor or clopidogrel.~7. Planned surgery during the study period.~8. Any of the following in the absence of a functioning implanted pacemaker: sick sinus syndrome, 2nd or 3rd degree AVB, documented syncope of suspected bradycardic origin.~9. Known clinically important thrombocytopenia or anemia.~10. Known pregnancy or lactation.~11. Condition which may either put the patient at risk or influence the result of the study.~12. Previous randomization in this SETFAST study.~13. Participation in another clinical study with an investigational product or device study over the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel arm (Type: ACTIVE_COMPARATOR): Clopidogrel 300 mg before PCI followed by 75 mg po OD
- Ticagrelor arm (Type: EXPERIMENTAL): Ticagrelor 180 mg before PCI followed by 90 mg po BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.~* Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.~* The subject has a radiographically measurable tumor.~* The subject is able to carry out daily life activities without difficulty.~* The subject is able to swallow and retain oral medication.~* The subject does not have significant side effects from previous anti-cancer treatment.~* The subject has adequate organ and blood cell counts.~* Sexually active subjects must use medically acceptable methods of contraception during the course of the study.~Exclusion Criteria:~* The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study.~* The subject has a brain tumor.~* Current severe, uncontrolled systemic disease.~* History of clinically significant heart, lung, or eye/vision problems.~* The subject has high blood pressure that is not well-controlled with medication.~* The subject has a permanent pacemaker.~* The subject is pregnant or breastfeeding.~* Positive for Hepatitis B, Hepatitis C, or HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): Trametinib plus Docetaxel
- Treatment Group 2 (Type: EXPERIMENTAL): Trametinib plus Erlotinib
- Treatment Group 3 (Type: EXPERIMENTAL): Trametinib plus Pemetrexed
- Treatment Group 4 (Type: EXPERIMENTAL): Trametinib plus Pemetrexed and Carboplatin
- Treatment Group 5 (Type: EXPERIMENTAL): Trametinib plus nab-Paclitaxel
- Treatment Group 6 (Type: EXPERIMENTAL): Trametinib plus Pemetrexed and Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Newborns with PPHN fulfilling the following:~1. born at ≥ 37 weeks gestational age.~2. birth weight between 2.5 and 4 kg.~3. post-natal age between 6 and 72 hours.~4. connected to mechanical ventilation with an oxygenation index (OI) \> 30 on two occasions at least 15 minutes apart.~5. documented PPHN confirmed by echocardiography.~Exclusion Criteria:~1. failure to obtain informed consent.~2. infants of mothers who received magnesium sulfate within 48 hours before labor.~3. congenital heart diseases (other than PDA and foramen ovale).~4. major congenital anomalies (including congenital diaphragmatic hernia and lung hypoplasia).~5. prior need for cardiopulmonary resuscitation.~6. mean arterial blood pressure (MABP) \< 35 mmHg despite therapy with volume infusions and inotrpic support.~7. impaired kidney function.~8. prior administration of pulmonary vasodilators.

- Gender: ALL
- Minimum Age: 6 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- NebMag (Type: EXPERIMENTAL): Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
- IVMag (Type: ACTIVE_COMPARATOR): Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years, both genders, without any previous treatment with statins or other lipid lowering drugs for at least 6 months~* With elevated triglycerides above 200 and below 800mg/dl and willing to follow all study procedures including assisting to clinics, fasting before blood samples and signing a written consent~Exclusion Criteria:~* High levels of low-density lipoprotein cholesterol (LDL-C)~* Unstable cardiovascular condition or awaiting a myocardial revascularization~* Congestive cardiac failure~* Uncontrolled diabetes~* Cancer~* Uncontrolled hypothyroidism~* Familial hypercholesterolemia~* Liver/muscle disease~* Pregnancy~* Other

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children of either gender, aged between 6 months (\> 5kg) and 10 years.~* Suffering from acute uncomplicated P. falciparum malaria confirmed by microscopy using Giemsa-stained thick film with an asexual parasite density of 1,000 to 100,000 parasites/μl.~* Presenting with fever (axillary temperature ≥ 37.5oC) or having a history of fever in the preceding 24 hours.~* Able to ingest tablets orally (either suspended in water or uncrushed with food).~* Willing to participate in the study with written assent from parent/guardian. Parental authorization will be obtained for children less than 8 years old and documented assent of parents/guardians for children 8-10 years.~* Willing and able to attend the clinic on stipulated regular follow-up visits.~Exclusion Criteria:~•Any of the following danger signs of severe malaria: Not able to drink or breast feed Persistent vomiting (\>2 episodes within previous 24 hours) Convulsions (\>1 episode within previous 24 hours) Lethargic/unconscious~* Signs/symptoms indicating severe/complicated malaria according to WHO criteria (WHO definition).~* Concomitant illnesses, underlying chronic hepatic or renal disease, abnormal cardiac rhythm, hypoglycaemia, jaundice, respiratory distress,~* Serious gastrointestinal disease, severe malnutrition (W/H \< 70%) or severe anaemia (haemoglobin \< 5 g/dl).~* Known hypersensitivity to the study drugs.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 120 Months
- Healthy Volunteers: f

Study Arms:
- Artesunate-Amodiaquine (Type: EXPERIMENTAL): As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
- Dihydroartemisinine_Piperaquine (Type: EXPERIMENTAL): As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
- Artemeter-Lumefantrine (Type: ACTIVE_COMPARATOR): This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 59 months~* Weight ≥ 5 kg~* P. falciparum monoinfection confirmed on a thick blood film~* Parasitic density between 1,000 and 200,000 asexual forms/µL of blood.~* Measured axillary temperature ≥ 37.5 ° C or history of fever during the previous 24 hours~* High probability of compliance with follow-up visits (no near-term travel plans)~* Consent of a parent or guardian who is at least 18 years of age.~* According to the group: in severely malnourished, weight-for-height z-score \<-3 SD or MUAC \<115 mm, and in non-severely malnourished, weight-for-height z-score ≥- 3 standard deviations (SD), and MUAC≥ 115 mm.~Exclusion Criteria:~* General danger signs or signs of complicated malaria as defined by the WHO (Appendix 1)~* Mixed or mono-infection with another Plasmodium species detected by microscopy~* Severe anemia (hemoglobin \<5 g / dL)~* Known underlying chronic or severe disease (e.g. cardiac, renal or hepatic disease, tuberculosis, sickle cell)~* Known HIV/AIDS infection~* Known history of hypersensitivity or contra-indication to any of the study medications: artemether, lumefantrine (first-line medications), or artesunate, amodiaquine (rescue medications)~* Presence of febrile conditions due to diseases other than malaria which could alter the outcome of the study~* History of a full treatment course with AL in the past 14 days.~* Height-for-age \<-3 Z scores~* Severe complications of malnutrition requiring hospitalization in intensive care or stabilization: Severe signs of kwashiorkor, Anorexia (failure to the appetite test), Hyperemesis, Severe acute infection, Hypothermia \<35 ˚ C (axillary) or hypoglycemia, Diarrhea with dehydration, Lethargy, coma, Clinical signs of vitamin A deficiency (xerophthalmia)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Artemether-Lumefantrine (Type: EXPERIMENTAL): All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female 2 month-old infants (55 - 89 days) on the day of consent.~2. Infants whose parents or legal guardians have voluntary given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.~3. Infants whose parents or legal guardians can comply with study procedures including follow-up~Exclusion Criteria:~1. Previously received any meningococcal A, C, W and Y vaccines.~2. Previous confirmed or suspected disease caused by N. meningitidis or who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection at any time since birth.~3. Progressive, unstable or uncontrolled clinical conditions.~4. A history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component, such as latex allergy.~5. Experienced significant acute or chronic infection within the previous 7 days or have experienced fever (temperature ≥ 38.0°C \[100.4°F\]) within the previous 3 days.~6. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~7. Received treatment with systemic administration corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth~8. Ever received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation (including Hepatitis B immune globulin) at any time since birth and for the full length of the study.~9. Any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw.~10. Any condition which, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.~11. Received or are planning to receive any investigational or non-registered medicinal product from birth and throughout the study.~12. Received oral or parenteral antibiotic treatment in the 3 days prior to the scheduled blood draw (topical antibiotics are acceptable, including antibiotic eye drops).~13. Relatives of site research staff working on this study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- MenACWY Group (Type: EXPERIMENTAL): Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of idiopathic Parkinson´s disease, and continuous treatment with commercially available rotigotine transdermal patch for at least 3 months, and a stable rotigotine dose including an 8 mg/24 h patch for at least 2 weeks prior to enrollment~Exclusion Criteria:~* Subjects has previously participated in this study, failed to be screened, or has participated in another study with an investigational medicinal product (IMP) or medical device within the last 30 days or is currently participating in such~* Subject with a history of significant skin hypersensitivity to adhesives, other transdermal products or recently unsolved contact dermatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A-B (Type: EXPERIMENTAL): 4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
- Sequence B-A (Type: EXPERIMENTAL): 4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete